Literature DB >> 32087145

Psychosocial Predictors of Glaucoma Medication Adherence Among the Support, Educate, Empower (SEE) Personalized Glaucoma Coaching Pilot Study Participants.

Mariam Salman1, Chris Andrews1, Michele Heisler2, Deborah Darnley-Fisch3, Paula Anne Newman-Casey4.   

Abstract

PURPOSE: To evaluate the association between baseline psychosocial milieu and subsequent glaucoma medication adherence among participants in the Support, Educate, Empower (SEE) personalized glaucoma coaching program pilot study.
DESIGN: Prospective cohort study.
METHODS: Participants (University of Michigan glaucoma patients aged ≥40 years, taking ≥1 glaucoma medication, who self-reported poor adherence) completed a baseline survey that assessed the following: (1) demographics; (2) social network; (3) perceived stress; (4) consideration of future consequences; (5) glaucoma-related distress; and (6) social support. Medication adherence was then monitored electronically for 3 months and the percentage of prescribed doses taken was calculated. The relationship between baseline factors and medication adherence was assessed using univariate and multivariate analysis. Main outcome measure was median percent adherence over 3 months.
RESULTS: Of the 95 study participants, 63% had graduated from college, 55% were white, 35% were African-American, and 97% had insurance. Median adherence over 3 months was 74% ± 21% (±standard deviation, SD). Higher income and more education were significantly associated with better adherence (P < .0001, P = .03). Glaucoma-related distress (mean score 5.6, SD = 3.0) was inversely associated with medication adherence on univariate (P < .0001) and multivariate analysis (P = .0002). Every 1-point increase in glaucoma-related distress score predicted a 2.4-percentage-point decrease in medication adherence.
CONCLUSIONS: Lower income, lower educational attainment, and a higher level of glaucoma-related distress all predicted lower adherence to glaucoma medications. Additional glaucoma self-management support resources should be directed toward patients with such risk factors for poor adherence.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32087145      PMCID: PMC7434652          DOI: 10.1016/j.ajo.2020.02.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  44 in total

1.  Why Patients With Glaucoma Lose Vision: The Patient Perspective.

Authors:  Paula A Newman-Casey; Roni M Shtein; Anne L Coleman; Leon Herndon; Paul P Lee
Journal:  J Glaucoma       Date:  2016-07       Impact factor: 2.503

2.  Back to the Consideration of Future Consequences Scale: time to reconsider?

Authors:  David R Rappange; Werner B F Brouwer; N Job A van Exel
Journal:  J Soc Psychol       Date:  2009-10

3.  Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma.

Authors:  Prakash Bhagav; Vaibhav Trivedi; Darshan Shah; Sajeev Chandran
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Development and validation of a predictive model for nonadherence with once-daily glaucoma medications.

Authors:  Dolly S Chang; David S Friedman; Travis Frazier; Ryan Plyler; Michael V Boland
Journal:  Ophthalmology       Date:  2013-03-28       Impact factor: 12.079

6.  Disease-related distress, self-care and clinical outcomes among low-income patients with diabetes.

Authors:  Anjali U Pandit; Stacy C Bailey; Laura M Curtis; Hilary K Seligman; Terry C Davis; Ruth M Parker; Dean Schillinger; Darren DeWalt; David Fleming; David C Mohr; Michael S Wolf
Journal:  J Epidemiol Community Health       Date:  2014-01-31       Impact factor: 3.710

7.  Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?

Authors:  Alan L Robin; David Covert
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

8.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983

9.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Authors:  M Cristina Leske; Anders Heijl; Mohamed Hussein; Bo Bengtsson; Leslie Hyman; Eugene Komaroff
Journal:  Arch Ophthalmol       Date:  2003-01

Review 10.  Importance of family/social support and impact on adherence to diabetic therapy.

Authors:  Tricia A Miller; M Robin Dimatteo
Journal:  Diabetes Metab Syndr Obes       Date:  2013-11-06       Impact factor: 3.168

View more
  3 in total

1.  Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India.

Authors:  G N Subathra; Sharmila R Rajendrababu; Vijayalakshmi A Senthilkumar; Iswarya Mani; B Udayakumar
Journal:  Indian J Ophthalmol       Date:  2021-05       Impact factor: 1.848

2.  Medication adherence, self-efficacy and health literacy among patients with glaucoma: a mixed-methods study protocol.

Authors:  Maria Achilleos; Anastasios Merkouris; Andreas Charalambous; Evridiki Papastavrou
Journal:  BMJ Open       Date:  2021-01-20       Impact factor: 2.692

3.  Demographic, Clinical, and Psychosocial Predictors of Change in Medication Adherence in the Support, Educate, Empower Program.

Authors:  David J Miller; Leslie M Niziol; Angela R Elam; Michele Heisler; Paul P Lee; Kenneth Resnicow; David C Musch; Deborah Darnley-Fisch; Jamie Mitchell; Paula Anne Newman-Casey
Journal:  Ophthalmol Glaucoma       Date:  2021-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.